Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Clinical trial NCT04034927 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04034927
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Fallopian Tube Endometrioid Tumor Fallopian Tube High Grade Serous Adenocarcinoma Malignant Ovarian Endometrioid Tumor Ovarian High Grade Serous Adenocarcinoma Platinum-Sensitive Fallopian Tube Carcinoma Platinum-Sensitive Ovarian Carcinoma Platinum-Sensitive Primary Peritoneal Carcinoma Primary Peritoneal High Grade Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Fallopian Tube Endometrioid Adenocarcinoma Recurrent Ovarian Endometrioid Adenocarcinoma Recurrent Ovarian Serous Adenocarcinoma

Start date: 2019-12-04
Primary completion: 2021-07-31
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.